Invasive pneumococcal disease in patients from a pediatric hospital in Peru, 2017-2020
OBJECTIVES.: Motivation for the study: there are few reports describing cases of invasive pneumococcal disease after the introduction of the 13-valent conjugate vaccine in Peru. Main findings: cases of invasive pneumococcal disease are still reported in children, more frequently in children under five years of age. The most frequent clinical form was bacteremia and there was greater antibiotic resistance to erythromycin, trimethoprim-sulfamethoxazole, and penicillin. Implications: our findings suggest the need to maintain epidemiological surveillance of invasive pneumococcal disease and to measure the impact of vaccination against pneumococcus in children. This study aimed to describe the clinical characteristics, serotypes, and antibiotic susceptibility in patients with invasive pneumococcal disease (IPD). The medical records of patients with IPD who were hospitalized at the Instituto Nacional de Salud del Niño-Breña (Lima, Peru) were reviewed. We evaluated 29 patients. The median age was 1.9 years (interquartile range: 1 to 4 years). Of the sample, 51.7% were women and the most frequent clinical form of IPD was bacteremia in 18 (62.1%) patients; 65.5% had a complete vaccination schedule, according to the Peruvian Ministry of Health. Germ isolation was performed from blood samples in 82.8% of patients. Antibiotic resistance to erythromycin (55.2%) was the most frequent, followed by resistance to trimethoprim-sulfamethoxazole (48.3%) and penicillin (24.1%). The isolated serotypes were 6C, 19A, 23A and 24F. One patient died of meningitis. In conclusion, IPD was more frequent in children aged one to five years and the most frequent clinical form was bacteremia. Five serotypes reported in previous studies were found to be resistant to penicillin and erythromycin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Revista peruana de medicina experimental y salud publica - 39(2022), 4 vom: 03. Okt., Seite 469-473 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Enfermedad neumocócica invasiva en pacientes de un hospital pediátrico de Perú, 2017-2020 |
|---|
| Beteiligte Personen: |
Marín-Portocarrero, Julio Guillermo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
63937KV33D |
|---|
| Anmerkungen: |
Date Completed 10.03.2023 Date Revised 10.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.17843/rpmesp.2022.394.12054 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353945404 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353945404 | ||
| 003 | DE-627 | ||
| 005 | 20231226061144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.17843/rpmesp.2022.394.12054 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353945404 | ||
| 035 | |a (NLM)36888810 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Marín-Portocarrero, Julio Guillermo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Invasive pneumococcal disease in patients from a pediatric hospital in Peru, 2017-2020 |
| 246 | 3 | 3 | |a Enfermedad neumocócica invasiva en pacientes de un hospital pediátrico de Perú, 2017-2020 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2023 | ||
| 500 | |a Date Revised 10.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES.: Motivation for the study: there are few reports describing cases of invasive pneumococcal disease after the introduction of the 13-valent conjugate vaccine in Peru. Main findings: cases of invasive pneumococcal disease are still reported in children, more frequently in children under five years of age. The most frequent clinical form was bacteremia and there was greater antibiotic resistance to erythromycin, trimethoprim-sulfamethoxazole, and penicillin. Implications: our findings suggest the need to maintain epidemiological surveillance of invasive pneumococcal disease and to measure the impact of vaccination against pneumococcus in children. This study aimed to describe the clinical characteristics, serotypes, and antibiotic susceptibility in patients with invasive pneumococcal disease (IPD). The medical records of patients with IPD who were hospitalized at the Instituto Nacional de Salud del Niño-Breña (Lima, Peru) were reviewed. We evaluated 29 patients. The median age was 1.9 years (interquartile range: 1 to 4 years). Of the sample, 51.7% were women and the most frequent clinical form of IPD was bacteremia in 18 (62.1%) patients; 65.5% had a complete vaccination schedule, according to the Peruvian Ministry of Health. Germ isolation was performed from blood samples in 82.8% of patients. Antibiotic resistance to erythromycin (55.2%) was the most frequent, followed by resistance to trimethoprim-sulfamethoxazole (48.3%) and penicillin (24.1%). The isolated serotypes were 6C, 19A, 23A and 24F. One patient died of meningitis. In conclusion, IPD was more frequent in children aged one to five years and the most frequent clinical form was bacteremia. Five serotypes reported in previous studies were found to be resistant to penicillin and erythromycin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Trimethoprim, Sulfamethoxazole Drug Combination |2 NLM | |
| 650 | 7 | |a 8064-90-2 |2 NLM | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 650 | 7 | |a Erythromycin |2 NLM | |
| 650 | 7 | |a 63937KV33D |2 NLM | |
| 650 | 7 | |a Penicillins |2 NLM | |
| 700 | 1 | |a Quispe-Sanchez, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Charca-Rodriguez, Flor de Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Atamari-Anahui, Noé |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista peruana de medicina experimental y salud publica |d 2007 |g 39(2022), 4 vom: 03. Okt., Seite 469-473 |w (DE-627)NLM203579194 |x 1726-4642 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:4 |g day:03 |g month:10 |g pages:469-473 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.17843/rpmesp.2022.394.12054 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 4 |b 03 |c 10 |h 469-473 | ||